secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monte Rosa Therapeutics, Inc. (GLUE)
CIK:        0001826457
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0000950170-23-061530
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monte Rosa Q3 net loss $34.9M; cash runway into H1 2026 after Roche deal and $25M offering
--------------------------------------------------------------------------------

- Net loss $34.9M vs $27.3M in Q3 2022; R&D expenses $28.3M, G&A $8.7M.
- Cash & securities $183M at Sep 30, 2023; excludes $50M Roche upfront and $25M direct offering received after quarter.
- Announced interim Phase 1/2 data for MRT-2359 showing tumor reductions in MYC-driven solid tumors; RP2 dose expected Q2 2024.
- Roche collaboration to discover MGDs; $50M upfront, potential milestones >$2B plus royalties.
- Discontinued sickle cell program; MRT-6160 IND submission planned 1H 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826457/000095017023061530/0000950170-23-061530-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826457/000095017023061530/glue-20231109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-061530

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer